Key result
Nano-formulated berberine enhances in vitro cardioprotection compared with free berberine.
Why the study?
Free berberine has limited clinical utility for myocardial infarction due to low bioavailability, poor myocardial targeting, and rapid systemic clearance.
Does polysaccharide-integrated nano-formulated berberine improve cardioprotective efficacy compared to free berberine in cardiomyocytes under ischemic conditions?
Does polysaccharide-integrated nano-formulated berberine improve cardioprotective efficacy compared to free berberine in cardiomyocytes under ischemic conditions?
Answers are grounded in this paper and cite their sources.
A novel multifunctional nanoplatform for berberine delivery shows enhanced cardioprotective efficacy in vitro, representing a promising approach for treating myocardial ischemia/reperfusion injury.
Myocardial infarction (MI) remains a leading cause of mortality, primarily due to ischemia/reperfusion injury and the limited regenerative capacity of cardiomyocytes. To overcome the limitations of free berberine (BBR)—such as low bioavailability, poor myocardial targeting, and rapid systemic clearance—we developed a multifunctional nanoplatform (1-CS@Zn-CPs@BBR) integrating chitosan, Zn(II)-based coordination polymers, and BBR. The design rationale was guided by recent advances in nanocarrier engineering and supported by literature evidence highlighting the importance of responsive delivery and biointerface stability under oxidative conditions. The constructed system demonstrates dual pH/ROS-responsive release, favorable electrochemical properties for real-time monitoring, and excellent biocompatibility. In vitro studies confirmed enhanced cardioprotective efficacy compared with free BBR, indicating improved delivery precision and cellular protection. Collectively, this work provides a well-supported and literature-informed strategy for integrating targeted delivery and electrochemical monitoring into a single nanoplatform, representing a promising and efficient alternative to conventional therapeutic approaches for myocardial injury.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2025) studied Myocardial infarction. 1-CS@Zn-CPs@BBR (polysaccharide-integrated nano-formulated berberine) vs. Free berberine was evaluated on Cardioprotective efficacy (in vitro). A multifunctional nanoplatform integrating chitosan, Zn(II)-based coordination polymers, and berberine demonstrated enhanced in vitro cardioprotective efficacy compared with free berberine.
Synapse has enriched 10 related papers. Consider them for comparative context: